Researchers Publish Encouraging Early Data on COVID-19 VaccinePosted on July 16th, 2020 by Dr. Francis CollinsCredit: NIHPeople all around the globe are anxiously awaiting development of a safe, effective vaccine to protect against the deadly threat of coronavirus disease 2019 (COVID-19). In the NIH-supported phase 1 human clinical trial, researchers found the vaccine, called mRNA-1273, to be safe and generally well tolerated. Importantly, human volunteers also developed significant quantities of neutralizing antibodies that target the virus in the right place to block it from infecting their cells. These encouraging results are being used to inform the next rounds of human testing of the mRNA-1273 vaccine. If you are interested in volunteering for these or other prevention trials, please check out NIH’s new COVID-19 clinical trials network.